Profile data is unavailable for this security.
About the company
Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.
- Revenue in GBP (TTM)1.21m
- Net income in GBP-3.19m
- Incorporated2015
- Employees56.00
- LocationOncimmune Holdings PLC1 Park RowLEEDS LS1 5ABUnited KingdomGBR
- Phone+44 11 5823 1869Fax+44 11 5823 1958
- Websitehttps://www.oncimmune.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
BSF Enterprise PLC | 67.24k | -1.71m |
Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
Oncimmune Holdings PLC | 1.21m | -3.19m |
Cambridge Nutritional Sciences PLC | 9.05m | -3.21m |
ImmuPharma PLC | 0.00 | -2.92m |
Genflow Biosciences PLC | 0.00 | -1.63m |
Kanabo Group PLC | 895.00k | -7.99m |
Destiny Pharma PLC | 0.00 | -5.66m |
Bivictrix Therapeutics PLC | 0.00 | -2.55m |
Chill Brands Group PLC | 146.62k | -3.64m |
Synairgen plc | 0.00 | -9.99m |
Genincode PLC | 2.16m | -7.02m |
Proteome Sciences plc | 5.03m | -2.44m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Hargreaves Lansdown Asset Management Ltd.as of 31 Aug 2023 | 3.14m | 4.23% |
Chelverton Asset Management Ltd.as of 31 Aug 2023 | 3.01m | 4.06% |
Unicorn Asset Management Ltd.as of 31 May 2024 | 1.16m | 1.57% |
Gabelli Funds LLCas of 28 Mar 2024 | 2.90k | 0.00% |